Regenerative Medicine
Ipamorelin / CJC-1295
Precision growth hormone release — deeper sleep, lean muscle, fat loss, and recovery.
The Ipamorelin/CJC-1295 combination is the gold-standard growth hormone secretagogue (GHS) protocol in regenerative medicine. Ipamorelin is a selective GHRP (Growth Hormone Releasing Peptide) that stimulates pulsatile GH release without raising cortisol or prolactin. CJC-1295 is a GHRH analog that amplifies and extends the GH pulse by saturating GHRH receptors. Together, they produce a synergistic, physiological GH release that optimizes sleep quality, body composition, recovery, and overall hormonal balance — without suppressing the body's own GH axis.
Mechanism: Ipamorelin binds the ghrelin receptor (GHSR) in the pituitary and hypothalamus, stimulating a clean, selective GH pulse. CJC-1295 (with DAC — Drug Affinity Complex) binds serum albumin, extending its half-life to 6–8 days, creating a sustained elevation in baseline GH release. Together, they work on complementary pathways to amplify both pulse height and base GH secretion. Dosing protocol: 200–300 mcg of each peptide administered subcutaneously before bed (aligned with the body's natural nocturnal GH pulse). Peptides are typically co-administered in the same injection. Cycle length: 3–6 months continuous use; many patients do 5-days-on/2-days-off dosing. Follow-up IGF-1 levels at 6–8 weeks confirm response and guide dose adjustment. Contraindications: Active malignancy (GH promotes IGF-1 which can drive cancer cell proliferation). Untreated hypothyroidism (GH response is blunted — thyroid optimization should precede or accompany). Diabetic retinopathy. Carpal tunnel syndrome may temporarily worsen with GH elevation. Not appropriate for competitive athletes subject to anti-doping regulations.
Key Benefits
Your Visit
What to expect
Hormone Baseline
IGF-1, fasting GH, and full hormone panel establish starting point and rule out contraindications.
Protocol Design
Ipamorelin 200–300 mcg + CJC-1295 200–300 mcg before bed. Injection training completed.
IGF-1 Response Check
IGF-1 level rechecked at 6–8 weeks. Dose titrated upward or maintained based on target range.
Sustained Protocol
3–6 month cycles with optional 5-on/2-off scheduling. Sleep quality, body composition, and recovery tracked.
Common Questions
Frequently asked
Is this the same as HGH injections?
No — Ipamorelin/CJC-1295 stimulates your own pituitary to produce GH naturally, preserving the pulsatile rhythm that synthetic HGH disrupts. It is safer, more physiological, and does not suppress the natural GH axis.
Will IGF-1 levels be monitored?
Yes — we check baseline IGF-1 before starting and recheck at 6–8 weeks. IGF-1 is the best indirect marker of GH optimization and guides dose titration.
Why take it before bed?
The pituitary releases the majority of daily GH during deep slow-wave sleep. Dosing before bed amplifies this natural pulse for maximum effect on tissue repair and body composition.
Can I use this alongside testosterone therapy?
Absolutely — Ipamorelin/CJC-1295 + testosterone is a comprehensive hormone optimization stack addressing both the GH and testosterone axes simultaneously for synergistic body composition and recovery benefits.
Start here
Book now to talk through whether ipamorelin / cjc-1295 is the right fit for your goals, timeline, and recovery plan.
Book now →Related Protocols